Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City
Human Papilloma Virus
About this trial
This is an interventional prevention trial for Human Papilloma Virus focused on measuring quadrivalent, vaccine
Eligibility Criteria
Inclusion Criteria:
- All those children whose parents accept their participation in the study.
Exclusion Criteria:
- Fever,
- previous vaccination against HPV,
- allergy to vaccine components,
- thrombocytopenia,
- immunosuppression,
- diarrhea,
- vomiting,
- dyscrasia,
- administration of another anti-viral vaccine in the previous 15 days.
Sites / Locations
- Malaquias Lopez CervantesRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Active Comparator
Cohort 1
Cohort 2
Cohort 3
11 year old boys enrolled in fifth grade of 40 public elementary schools of Mexico City, from the political demarcations of Azcapotzalco, Gustavo A. Madero, Iztacalco, Miguel Hidalgo, Venustiano Carranza, Iztacalco and Tlalpan, reciving a two-dose vaccination scheme (0-6). 250 subjects will be recruited.
Historical cohort of young women 18-24 years old recruited by Lazcano et. al. receiving a standard vaccination schedule (0-1-6 months). 500 subjects were recruited.
11 year old girls enrolled in fifth grade of 40 public elementary schools of Mexico City, from the political demarcations of Azcapotzalco, Venustiano Carranza, Iztacalco and Tlalpan, reciving a two-dose vaccination scheme (0-6). 250 subjects will be recruited.